You are here: Industry Insights > Sihuan Pharmaceutical

News List

Sihuan Pharmaceutical (0460.HK): Establishment of Joint Venture with Bluepha Co., Ltd. prnasia
January 21, 2022
Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group:" Hong Kong Stock Exchange Stock Code: 0460) ...
Sihuan Pharmaceutical (0460.HK) receives approval for its exclusive medical aesthetic product Letybo (botulinum toxin), A blockbuster product in a hundred-billion size market prnasia
October 28, 2020
Sihuan Pharmaceutical Holdings Group Ltd. is pleased announce that "Type A Botulinum Toxin for Injection" (Letybo 100U), a product exclusively distributed by Sihuan Pharmaceutical, has officially received the marketing approval from the ...
Sihuan Pharmaceutical's Gabapentin Capsules was Granted Drug Production Approval, the Third Company Obtained Approval in China prnasia
October 22, 2020
Sihuan Pharmaceutical Holdings Group Ltd. is pleased to announce that the National Medical Products Administration has granted drug production approval for the Group's gabapentin capsules.
Sihuan Pharmaceutical Invests in Phase I Fund of Ascendum Capital Life Technology to Expand its Strategy in Development of Innovative Drugs prnasia
October 21, 2020
On 20 October 2020, Sihuan Pharmaceutical Holdings Group Ltd. announced that its participation in the investment of Phase I Fund of Ascendum Capital Life Technology.
Drug Registration Approval Granted for Sihuan Pharmaceutical's Pediatric Compound Amino Acid Injection (18AA-II) prnasia
March 23, 2020
Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that drug registration approval has been granted by the National Medical Products Adminis
Sihuan Pharmaceutical Announces Clinical Research of Favipiravir, Co-Developed with the Academy of Military Medical Sciences of the People's Liberation Army, Has Commenced prnasia
March 02, 2020
The Trials was officially initiated by the Ministry of Science and Technology in early February. The Human Genetic Resources Management Office of the PRC urgently reviewed the Trials and the Group obtained the human genetic resources administrative licens
Sihuan Pharmaceutical: Production Approval Granted For Rivastigmine Hydrogen Tartrate Capsule, The First Drug Passing Consistency Evaluation And Levetiracetam Tablet And The First Registration Approval Granted For Midazolam Oromucosal Solution prnasia
February 18, 2020
The approved dosage forms of rivastigmine hydrogen tartrate capsule are 1.5 mg and 3.0 mg and is used for the treatment of mild to moderate Alzheimer's dementia.
Sihuan Pharmaceutical Accelerates Product Expansion in Digestive System and Liver Related Diseases prnasia
February 14, 2020
Anaprazole sodium is the only self-developed proton pump inhibitor ("PPI") in the PRC, with Chinese and international patents.
Sihuan Pharmaceutical and Hetero Labs Limited Reached A Framework Cooperation Agreement in Pharmaceutical Manufacturing Area prnasia
February 12, 2020
Backed by over 25 years of expertise in the pharmaceutical industry, Hetero is the world's leading producer of anti-retroviral drugs for the treatment of HIV/AIDS. Hetero caters about 40% of the identified HIV/AIDS patients globally through around 30 anti
Sihuan Pharmaceutical(0460.HK): Respond to the special directives to combat illegal medical aesthetics services, Advocate 'Positive Energy' of China's Medical Aesthetics Industry ACN Newswire
September 09, 2021
HONG KONG, Aug 11, 2021 - (ACN Newswire) - On June 10, 2021, the National Health Commission, leading eight ministries and commissions, issued the "Notice on Distributing the Special Rectification Work Plan for Combating Illegal Medical Aesthetic Services.